Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 14/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.43 |
| ▸ | JAK2 | O60674 | 5/20 | 0.40 |
| ▸ | JAK1 | P23458 | 5/20 | 0.40 |
| ▸ | TYK2 | P29597 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227729 | 0.89 | TYK2 (0.49) | PLK4NTRK1JAK2JAK1TYK2 | |
| SCHEMBL22055393 | 0.89 | TYK2 (0.49) | PLK4NTRK1JAK2JAK1TYK2 | |
| SCHEMBL23878890 | 0.89 | TYK2 (0.49) | PLK4NTRK1JAK2JAK1TYK2 | |
| SCHEMBL22055257 | 0.88 | AURKA (0.49) | NTRK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL24071710 | 0.83 | AURKA (0.46) | NTRK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL24995571 | 0.82 | PAK1 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22054963 | 0.77 | TYK2 (0.56) | NTRK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL23878843 | 0.77 | TYK2 (0.56) | NTRK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22055392 | 0.76 | PLK4 (0.44) | PLK4NTRK1JAK2JAK1TYK2 | |
| SCHEMBL22054597 | 0.76 | AURKA (0.49) | NTRK1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | PLK4 2282/4885NTRK1 2151/4885JAK2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.